Skip to content

Clinical Trial of Orthokeratology Lens (MCOK-01)

Clinical Trial of Orthokeratology Lens (MCOK-01)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06037850
Enrollment
390
Registered
2023-09-14
Start date
2022-07-29
Completion date
2024-10-31
Last updated
2025-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

A prospective, multicenter, randomized, controlled clinical trial of orthokeratology lens

Detailed description

The test product is the orthokeratology lens, and the control product is a commercially available orthokeratology lens. The number of enrolled subjects is 390, and clinical observation is performed for 12 months.

Interventions

DEVICETest orthokeratology lens

Randomized to test orthokeratology lens worn during sleep every night

DEVICEControl orthokeratology lens

Randomized to control orthokeratology lens worn during sleep every night

Sponsors

Menicon Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients with myopia and myopic astigmatism 2. Those who are not willing to wear glasses in daily life 3. Fully understand of the purpose of the clinical trial and agree to sign the informed consent form to participate in clinical trials, based on his/her willingness 4. Those who can visit the institution on scheduled dates 5. Those who can receive guidance and tests as required by the investigator 6. Those who fully understand and follow the instructions of the lenses for this clinical trial

Exclusion criteria

\<At screening\> 1. Best corrected vision acuity of less than 0.8 with spectacles 2. Subjective refraction test shows spherical power greater than -6.00D,less than -0.50D or astigmatism greater than 1.5D 3. Patients in need of treatment for eye disease other than refractive error (excluding those receiving artificial tears eye drops due to the wearing of corneal contact lenses) 4. The medical history of intraocular surgery that may affect the effect of wearing the lens for this clinical trial (those with corneal transplantation, Retinal detachment, etc.) 5. The medical history of refractive corneal surgery 6. Those in need of a strength out of the scope of lens for this clinical trial 7. Having eye allergic diseases that may cause disorders in wearing the lenses for this clinical trial 8. All Corneal abnormalities including keratoconus, corneal dystrophy, previous history of ocular herpes infections, acute dry eyes, low corneal endothelial cell counts. 9. Pregnant (judgment according to her known information) or those who plan to become pregnant during clinical trial, or those who are breast feeding 10. Those who are participating in other clinical trials or have participated in other clinical trial in the past 30 days 11. Prior experience with use of rigid lenses within the previous 3 weeks or use of soft lenses within the previous 3 days 12. Prior experience with myopia control treatment (e.g. atropine, orthokeratology, multifocal soft contact lenses) 13. Minor/adult subjects who lack mental capacity 14. Other not suitable for this clinical trial at investigator's discretion \<At the beginning of the wearing\> (1) Those who are determined to be unable to obtain good centralized positioning even though changing strength (2) Pregnancy confirmed (3) Those who are difficult in continuing the clinical trial at investigator's discretion

Design outcomes

Primary

MeasureTime frameDescription
Visual acuity1 yearuncorrected visual acuity measured using logMAR chart
Axial length1 yearaxial eye length in millimeter measured by MYAH (Topcon) and IOL master (ZEISS)
Refraction1 yearspherical and cylinder power in diopter for best corrected visual acuity measured subjectively

Secondary

MeasureTime frameDescription
Adverse Events1 yearAdverse events are classified into moderate, middle, or severe.

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026